On 25 May 2018, orphan designation (EU/3/18/2017) was granted by the European Commission to Celgene Europe Limited, United Kingdom, for autologous CD4+ and CD8+ T cells expressing a CD19-specific chimeric antigen receptor (also known as JCAR017) for the treatment of follicular lymphoma.
This medicine is now known as lisocabtagene maraleucel.
Please note that this product (marketed as Breyanzi) was withdrawn from the Union Register of orphan medicinal products in February 2022 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.
Follicular lymphoma is a cancer of a type of white blood cell called B lymphocytes or B cells. In follicular lymphoma, the B cells multiply quickly and live for too long, so there are too many of them in the lymph nodes. The first sign of the disease is usually a lump in the neck, under the arm or in the groin area, caused by an enlarged lymph node. Patients may also have fever, weight loss, tiredness and night sweats.
Follicular lymphoma is usually diagnosed in people aged over 50 years. It is a long-term debilitating and life-threatening disease due to organ damage and the cancer coming back.
At the time of designation, follicular lymphoma affected approximately 3.8 in 10,000 people in the European Union (EU). This was equivalent to a total of around 197,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).
*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 28), Norway, Iceland and Liechtenstein. This represents a population of 517,400,000 (Eurostat 2018).
At the time of designation, the main treatments for follicular lymphoma available in the EU included chemotherapy (medicines to treat cancer) combined with immunotherapy (medicines that stimulate the body's own immune system to kill the cancer cells). The medicines ibritumomab tiuxetan, idelalisib, interferon alfa-2b, obinutuzumab, pixantrone and rituximab were authorised for the treatment of follicular lymphoma.
The sponsor has provided sufficient information to show that the medicine might be of significant benefit for patients with follicular lymphoma because early results had shown prolonged responses in patients whose disease had come back after, or not responded to, other treatments. This assumption will need to be confirmed at the time of marketing authorisation, in order to maintain the orphan status.
The abnormal B cells in patients with follicular lymphoma produce a protein on their surface called CD19.
This medicine is made up of two types of immune cells (called CD4+ and CD8+ T cells) which are taken from the patient. The T cells are modified in the laboratory with a virus that carries a gene into the T cells that allows them to target CD19. The modified T cells are then grown to increase their numbers. When given back to the patient, the T cells are expected to attach to CD19 on the cancer cells and kill them. These T cells are also expected to activate other T cells from the patient to act against the cancer cells.
The virus used to carry the gene into the cells has been modified so that it cannot reproduce and cause disease in humans.
The effects of this medicine have been evaluated in experimental models.
At the time of submission of the application for orphan designation, clinical trials with the medicine in patients with follicular lymphoma were ongoing.
At the time of submission, the medicine was not authorised anywhere in the EU for follicular lymphoma. Orphan designation of the medicine had been granted in the United States for the condition.
In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 19 April 2018 recommending the granting of this designation.
Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.
Bristol-Myers Squibb Pharma EEIG
Plaza 254
Blanchardstown Corporate Park 2
Dublin 15
D15 T867
Ireland
Tel. +353 1 483 3857
E-mail: medical.information@bms.com
The Committee for Orphan Medicinal Products reviewed the orphan designation of product at the time of marketing authorisation.
The sponsor formally requested the withdrawal of the orphan designation prior to the Committee’s final opinion. More information is available in the 
Breyanzi : Orphan maintenance assessment report (initial authorisation).
| Date | Update |
|---|---|
| February 2022 | This product was withdrawn from the Union Register of orphan medicinal products on request of the Sponsor. |
| January 2021 | The sponsorship was transferred to Bristol-Myers Squibb Pharma EEIG, Ireland |
| February 2019 | The sponsorship was transferred to Celgene Europe B.V., the Netherlands |
EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: